Clinical Trials: Lymphomas

California

Duarte; City of Hope
COG AHOD0031: A Phase III Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease

Duarte; City of Hope
Prospective Chart Review for Data Inclusion into Sentinel Node Working Group

Duarte; City of Hope
Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation, AnorMED Protocol, AMD3100-CUP001

Duarte; City of Hope
A Phase I/II Study of VELCADE in Combination with Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma

Duarte; City of Hope
COG A003: Phase I trial and pharmacokinetic study of arsenic trioxide in pediatric patients with refractory leukemia or lymphoma

Duarte; City of Hope
Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Volunteer Donors for Use in T Cell Program

La Jolla; Moores UCSD Cancer Center
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

San Diego; Scripps Clinic
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Illinois

Chicago; University of Chicago
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago; Northwestern University
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Chicago; Rush University
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Massachusetts

Boston; Dana-Farber Cancer Institute
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Michigan

Ann Arbor; University of Michigan
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Detroit; Barbara Ann Karmanos Cancer Institute
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

New York

New York; Mount Sinai Medical Center
A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas

New York; Columbia-Presbyterian Medical Center
Study of donor leukocyte infusions in patients with recurrent or persistent hematological malignancies after allogeneic bone marrow transplantation.

New York; Columbia-Presbyterian Medical Center
Study of the use of peripheral blood stem cells for allogeneic transplantation (PBSCT) in patients with advanced hematological malignancies at increased risk of relapse or transplant-related mortality

New York; Columbia-Presbyterian Medical Center
Study of standard chemotherapy and radiotherapy before allogeneic stem cell transplantation

New York; Columbia-Presbyterian Medical Center
Study of tandem high dose chemotherapy and autologous blood stem cell transplantation for lymphoma

New York; Columbia-Presbyterian Medical Center
Study of transplantation using umbilical cord and placental blood

North Carolina

Chapel Hill; University of North Carolina
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Durham; Duke University
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Ohio

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
(ANHL06P1) A Phase I/II Pilot Study of Ifosfamide, Carboplatin, Etoposide, and Monoclonal Antibody SGN-30 in Pediatric Patients with CD30-Positive Recurrent Anaplastic Large Cell Lymphoma

Cleveland; Case Western Reserve University Ireland Cancer Center
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Columbus; The Ohio State University
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Oregon

Portland; Oregon Health & Science University
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Pennsylvania

Philadelphia; Temple University
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Pittsburgh; The University of Pittsburgh Medical Center (UPMC)
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

South Carolina

Greenville; Cancer Centers of the Carolinas
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Texas

Houston; University of Texas
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Central Nervous System Lymphoma

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Mantle Zone Lymphoma

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Primary Lymphoma Of The Gastrointestinal Tract

International

Greenfield Park, QC, Canada; Research Site:
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Quebec City, QC, Canada; Research Site:
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.

Hillerød, Denmark; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

København, Denmark; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Creteil, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Le Mans, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Lille, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Montpellier, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Nantes, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Paris, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Pessac, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Pierre Benite, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Rennes, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Rouen, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Toulouse, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Tours, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Vandoeuvre-Les-Nancy, France; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Essen, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Heidelberg, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Kiel, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Köln, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Mainz, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

München, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Münster, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Ulm, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Würzburg, Germany; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Haifa, Israel; Rambam Healthcare Campus
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Jerusalem, Israel; Hadassah Medical Organization
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Tel-Hashomer, Israel; Chaim Sheba Medical Center
A Study of the Monoclonal Antibody CT-011 in Diffuse Large B-Cell Lymphoma Following Autologous Stem Cell Transplantation.

Bergen, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Oslo, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Stavanger, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Tromsø, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Trondheim, Norway; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Barcelona, Spain; Research Site:
A Dose-Escalating Study of R7159 in Patients With CD20+ Malignant Disease.

Eskilstuna, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Falun, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Halmstad, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Huddinge, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Jonkoping, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Karlstad, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Linkoeping, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lulea, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Lund, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Malmoe, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Oerebro, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Stockholm, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Sundsvall, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Umea, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Uppsala, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Västerås, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Vaxjo, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma

Visby, Sweden; Research Site:
A Study of MabThera (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma